HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAorphan designation65% confidence

Medical Products for Rare Diseases and Conditions

Source: FDA

Why This Matters

Why this matters: provides agency context on orphan designation that may shape timing or evidence expectations for Roche.

Regulatory Analysis

Supporting Context

Therapeutic area
Neurology · Alzheimer's Disease
Sub-indication
General

Related signal: Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

Source

View source document

Related Signal

Open signal — Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.